oxybutynin has been researched along with thiophenes in 74 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (4.05) | 29.6817 |
| 2010's | 67 (90.54) | 24.3611 |
| 2020's | 4 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Rovner, ES; Wein, AJ | 1 |
| Cardozo, L; Cartwright, R; Robinson, D; Vella, M | 1 |
| Kane, RL; Shamliyan, TA; Wilt, TJ; Wyman, J | 1 |
| Häck, HJ; Leffers, KW; Schnitzler, A | 1 |
| Allen, RP; Becker, P; Bogan, R; Fichtner, A; Fry, JM; Hening, WA; Kudrow, DB; Lesh, KW; Ondo, WG; Schollmayer, E; Walters, AS; Winkelman, JW | 1 |
| Benes, H; Cassel, W; Ferini-Strambi, L; Fichtner, A; Garcia-Borreguero, D; Högl, B; Kohnen, R; Montagna, P; Oertel, WH; Partinen, M; Penzel, T; Poewe, W; Polo, O; Saletu, B; Schollmayer, E; Sixel-Döring, F; Stiasny-Kolster, K; Trenkwalder, C | 1 |
| Beneš, H; García-Borreguero, D; Geisler, P; Högl, B; Kohnen, R; Oertel, WH; Poewe, W; Schollmayer, E; Stiasny-Kolster, K; Trenkwalder, C | 1 |
| Armstrong, EP; Malone, DC; McCarberg, B; Panarites, CJ; Pham, SV | 1 |
| Beneš, H; Ferini-Strambi, L; Fichtner, A; García-Borreguero, D; Högl, B; Kohnen, R; Oertel, W; Poewe, W; Schollmayer, E; Stiasny-Kolster, K; Trenkwalder, C | 1 |
| Ahrweiler, S; Braun, M; Cawello, W; Sulowicz, W; Szymczakiewicz-Multanowska, A | 1 |
| Sanford, M; Scott, LJ | 2 |
| Boroojerdi, B; Ghys, L; Surmann, E; Whitesides, J | 1 |
| Patel, TA; Rastogi, R; Swarm, RA | 1 |
| Perez-Lloret, S; Rascol, O; Ratti, PL; Rey, MV | 1 |
| Poewe, W; Seppi, K; Sprenger, FS | 1 |
| Bernardi, G; Caltagirone, C; Di Lorenzo, F; Esposito, Z; Koch, G; Lo Giudice, T; Martorana, A | 1 |
| Bauer, L; Dohin, E; Ferini-Strambi, L; Fichtner, A; García-Borreguero, D; Högl, B; Schollmayer, E | 1 |
| Boroojerdi, B; Giladi, N; Surmann, E | 1 |
| Alba-Alcántara, L; Bermejo, PE; Ruiz-Huete, C; Zea, MA | 1 |
| Bachmann, CG; Berg, D; Berkels, R; Grieger, F; Hofmann, WE; Lauterbach, T; Schollmayer, E; Stiasny-Kolster, K | 1 |
| Coppola, G; Di Lorenzo, C; Pierelli, F | 1 |
| Waters, C | 1 |
| Chen, ZM; Lei, P; Li, FQ; Li, SS; Peng, GG; Zhou, CQ | 1 |
| Arth, C; Bauer, L; Brunnert, M; Elshoff, JP; Komenda, M; Schmid, M; Timmermann, L | 1 |
| Boekens, H; Braun, M; Cawello, W; Fichtner, A | 1 |
| Braun, M; Cawello, W; Elshoff, JP; Funaki, T; Ikeda, J; Kim, SR | 1 |
| Bogan, RK | 1 |
| Binetti, G; Frisoni, GB; Moretti, DV; Zanetti, O | 1 |
| Hadgraft, J; Lane, ME; McAfee, DA | 1 |
| Berkels, R; Grieger, F; Kassubek, J; Lauterbach, T; Müller, T; Timmermann, L; Woitalla, D | 1 |
| Berkels, R; Grieger, F; Lauterbach, T; Lorenzl, S; Sieb, JP; Themann, P; Warnecke, T | 1 |
| Braun, M; Cawello, W; Elshoff, JP; Funaki, T; Ikeda, J; Kim, SR; Masahiro, T | 1 |
| Andreas, JO; Braun, M; Cawello, W; Elshoff, JP; Jang, IJ; Kim, BH; Kim, JR; Soo Lim, K; Yu, KS | 1 |
| Andreas, JO; Braun, M; Cawello, W; Elshoff, JP; Mathy, FX | 1 |
| Antonini, A; Bauer, L; Chaudhuri, KR; Dohin, E; Oertel, WH; Rascol, O; Reichmann, H; Schmid, M; Singh, P; Tolosa, E | 1 |
| Liguori, C; Marciani, MG; Mercuri, NB; Pierantozzi, M; Placidi, F; Stanzione, P; Stefani, A | 1 |
| Asgharnejad, M; Bauer, L; Chaudhuri, KR; Dohin, E; Nilius, S; Rascol, O; Surmann, E; Zesiewicz, T | 1 |
| Benes, H; Berkels, R; Canelo, M; Heidbrede, T; Kelling, D; Lang, M; Schollmayer, E; Schroeder, H; Trenkwalder, C | 1 |
| Andreas, JO; Braun, M; Cawello, W; Elshoff, JP | 1 |
| Bauer, A; Bauer, L; Benes, H; Carney, HC; Cassel, W; Grieger, F; Joeres, L; Kesper, K; Moran, K; Oertel, W; Rye, D; Schollmayer, E; Sica, D; Trenkwalder, C; Walters, AS; Whitesides, J; Winkelman, JW | 1 |
| Asgharnejad, M; Bauer, L; Chen, S; Du, X; Hu, X; Shang, HF; Surmann, E; Zhang, ZX; Zhao, Z | 1 |
| Ferini-Strambi, L; Galbiati, A; Marelli, S | 1 |
| Asgharnejad, M; Barone, P; Bauer, L; Dohin, E; Hauser, RA; Slawek, J; Surmann, E | 1 |
| Asgharnejad, M; Bauer, L; Chung, SJ; Jeon, B; Ramirez, F | 1 |
| Garnock-Jones, KP | 1 |
| Guillot, B; Raison-Peyron, N | 1 |
| Chen, Y; Lan, D; Wang, Y; Wu, H; Yang, Y; Zhao, Z | 1 |
| Mackie, SE; Mei, LA; Platt, S; Schoerning, L; Winkelman, JW | 1 |
| Asgharnejad, M; Bauer, L; Benitez, A; Boroojerdi, B; Chung, SJ; Heidbrede, T; Kim, HJ; Little, A | 1 |
| Anan, C; Bhidayasiri, R; Boonpang, K; Chaiwong, S; Jagota, P; Leaknok, A; Penkeaw, N; Rattanachaisit, W; Saksornchai, K; Sringean, J; Thanawattano, C | 1 |
| Asgharnejad, M; Bauer, L; Liu, CF; Liu, YM; Shao, M; Surmann, E; Tao, EX; Wang, J; Xue, HB; Zhang, ZX | 1 |
| D'Elia, A; Imbriani, P; Pisani, A; Schirinzi, T | 1 |
| Fujioka, S; Hara, K; Kamimura, H; Kiyomi, F; Ogata, K; Shibaguchi, H; Tsuboi, Y; Yasutaka, Y | 1 |
| Andreas, JO; Braun, M; Cawello, W | 1 |
| Bauer, L; Elshoff, JP; Goldammer, N; Oortgiesen, M; Pesch, H; Timmermann, L | 1 |
| Asgharnejad, M; Badea, L; Bauer, L; Grieger, F; Markowitz, M; Müller, T; Nondonfaz, X; Timmermann, L; Tolosa, E | 1 |
| Zarola, F | 1 |
| Hattori, N; Ogawa, T; Oyama, G | 1 |
| Di Lazzaro, G; Imbriani, P; Pisani, A; Pisani, V; Scalise, S; Schirinzi, T | 1 |
| He, Y; Wang, HT; Wang, L; Yu, G | 1 |
| Hindmarsh, J; Hindmarsh, S; Lee, M; Telford, R | 1 |
| Egawa, G; Kabashima, K; Nomura, T; Takeuchi, A | 1 |
| Boroojerdi, B; Carson, S; Heldman, D; Isaacson, SH; Klos, K; Kreitzman, DL; Markowitz, M; McGraw, M; Phillips, M; Revilla, FJ; Terricabras, D; Truong, D; Waln, O; Woltering, F | 1 |
| Anticoli, S; Dalmaso, SG; Marchitto, N; Pannozzi, A; Raimondi, G; Sindona, F | 1 |
| Frampton, JE | 1 |
| Ding, ZT; Fei, L; Zhou, D | 1 |
| Fukuda, K; Hirano, M; Isono, C; Kusunoki, S; Nakamura, Y; Ueno, S | 1 |
| Fang, L; Liu, C; Qu, X; Shang, R; Song, L; Wan, X | 1 |
| Boura, I; Chaudhuri, KR; Jenner, P; Klingelhoefer, L; Leta, V; Raeder, V; Reichmann, H; Trenkwalder, C | 1 |
| Hindmarsh, J; Hindmarsh, S; Lee, M | 1 |
| Ann Natividad, J; Chaudhuri, KR; Chung-Faye, G; Lau, YH; Leta, V; Metta, V; Parry, M; Rukavina, K | 1 |
21 review(s) available for oxybutynin and thiophenes
| Article | Year |
|---|---|
Update on overactive bladder: pharmacologic approaches on the horizon.
Topics: Administration, Cutaneous; Administration, Intravesical; Administration, Oral; Adrenergic beta-3 Receptor Antagonists; Benzhydryl Compounds; Benzilates; Benzofurans; Botulinum Toxins; Cresols; Dosage Forms; Dose-Response Relationship, Drug; Drug Compounding; Drug Evaluation; Duloxetine Hydrochloride; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropanes; Phenylpropanolamine; Pyrrolidines; Thiophenes; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder Diseases; Urination Disorders | 2003 |
New developments in the treatment of urinary incontinence.
Topics: Administration, Cutaneous; Adrenergic Uptake Inhibitors; Benzofurans; Drug Therapy, Combination; Duloxetine Hydrochloride; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrrolidines; Quality of Life; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Thiophenes; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence, Stress | 2006 |
Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Collagen; Cresols; Duloxetine Hydrochloride; Electric Stimulation Therapy; Estrogen Replacement Therapy; Exercise Therapy; Female; Humans; Magnetics; Mandelic Acids; Pelvic Floor; Pessaries; Phenylpropanolamine; Randomized Controlled Trials as Topic; Thiophenes; Tolterodine Tartrate; Urinary Incontinence | 2008 |
Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
Topics: Administration, Topical; Amines; Anesthetics, Local; Antidepressive Agents, Tricyclic; Capsaicin; Clinical Trials as Topic; Costs and Cost Analysis; Cyclohexanecarboxylic Acids; Dopamine Uptake Inhibitors; Duloxetine Hydrochloride; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Lidocaine; Male; Markov Chains; Neuralgia, Postherpetic; Pregabalin; Quality of Life; Sensory System Agents; Thiophenes; Transdermal Patch | 2011 |
Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2011 |
Case scenario: opioid association with serotonin syndrome: implications to the practitioners.
Topics: Analgesics, Opioid; Antidepressive Agents, Tricyclic; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Depressive Disorder; Desipramine; Drug Interactions; Duloxetine Hydrochloride; Fentanyl; Humans; Male; Methadone; Middle Aged; Oxycodone; Polypharmacy; Pyrazoles; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Sulfonamides; Thiophenes; Transdermal Patch | 2011 |
Spotlight on rotigotine transdermal patch in Parkinson's disease.
Topics: Animals; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2011 |
Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2013 |
Drug safety evaluation of rotigotine.
Topics: Administration, Cutaneous; Antiparkinson Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine Agonists; Evidence-Based Medicine; Humans; Parkinson Disease; Patient Safety; Risk Assessment; Risk Factors; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2012 |
The development of the rotigotine transdermal patch: a historical perspective.
Topics: Animals; Dopamine Agonists; Drug Evaluation, Preclinical; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2013 |
Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.
Topics: Dopamine Agonists; Humans; Parkinson Disease; Placebos; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Topics: Administration, Cutaneous; Dopamine Agonists; Drug Delivery Systems; Humans; PubMed; Restless Legs Syndrome; Sleep; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; United States; United States Food and Drug Administration | 2014 |
Rotigotine: the first new chemical entity for transdermal drug delivery.
Topics: Administration, Cutaneous; Chemical Phenomena; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Humans; Molecular Structure; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2014 |
An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Comorbidity; Dopamine Agonists; Drug Interactions; Evidence-Based Medicine; Humans; Parkinson Disease; Practice Guidelines as Topic; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2015 |
Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
Topics: Administration, Cutaneous; Animals; Dopamine Agonists; Drug Delivery Systems; Humans; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Time Factors; Transdermal Patch | 2016 |
Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
Topics: Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Time Factors; Transdermal Patch; Treatment Outcome | 2016 |
Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
Topics: Dopamine Agonists; Drug Substitution; Humans; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials.
Topics: Dopamine Agonists; Humans; Mental Disorders; Parkinson Disease; Psychotropic Drugs; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2018 |
Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pramipexole; Quality of Life; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2019 |
The efficacy and safety of rotigotine transdermal patch for the treatment of sleep disorders in Parkinson's disease: a meta-analysis.
Topics: Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2019 |
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Parkinson Disease; Quality of Life; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2021 |
29 trial(s) available for oxybutynin and thiophenes
| Article | Year |
|---|---|
High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Male; Parkinson Disease; Patient Compliance; Patient Satisfaction; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2010 |
Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States.
Topics: Adolescent; Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Restless Legs Syndrome; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome; United States; Young Adult | 2010 |
Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Movement; Polysomnography; Restless Legs Syndrome; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome; Young Adult | 2010 |
Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.
Topics: Adult; Aged; Dopamine Agonists; Female; Humans; Male; Middle Aged; Patient Compliance; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Young Adult | 2010 |
Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Double-Blind Method; Female; Follow-Up Studies; Headache; Humans; Male; Middle Aged; Nasopharyngitis; Prospective Studies; Restless Legs Syndrome; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Time Factors; Transdermal Patch; Treatment Outcome; Young Adult | 2011 |
Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function.
Topics: Adult; Aged; Area Under Curve; Case-Control Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Renal Insufficiency; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2012 |
Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline.
Topics: Dopamine Agonists; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Quality of Life; Severity of Illness Index; Sleep; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2011 |
Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Cholinergic Neurons; Dopamine Agonists; Dose-Response Relationship, Drug; GABAergic Neurons; Humans; Middle Aged; Neural Inhibition; Neuronal Plasticity; Nootropic Agents; Receptors, Dopamine D2; Single-Blind Method; Synaptic Transmission; Tetrahydronaphthalenes; Thiophenes; Transcranial Magnetic Stimulation; Transdermal Patch | 2013 |
Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years.
Topics: Administration, Cutaneous; Adult; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; International Cooperation; Male; Middle Aged; Prospective Studies; Restless Legs Syndrome; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Topics: Adolescent; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Survival Analysis; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.
Topics: Aged; Benzothiazoles; Dopamine Agonists; Female; Germany; Humans; Levodopa; Male; Middle Aged; Pramipexole; Restless Legs Syndrome; Self Administration; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations.
Topics: Adult; Biological Availability; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Humans; Male; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2013 |
Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.
Topics: Administration, Cutaneous; Adult; Area Under Curve; Biological Availability; Biotransformation; Dopamine Agonists; Humans; Hungary; Liver; Liver Diseases; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Risk Assessment; Severity of Illness Index; Slovakia; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2014 |
Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
Topics: Administration, Cutaneous; Adult; Area Under Curve; Asian People; Dopamine Agonists; Female; Half-Life; Humans; Male; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; White People; Young Adult | 2014 |
Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Dopamine Agonists; Follow-Up Studies; Humans; Parkinsonian Disorders; Psychiatric Status Rating Scales; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2014 |
Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pain Measurement; Parkinson Disease; Patient Satisfaction; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2015 |
Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Caregivers; Cross-Sectional Studies; Dopamine Agonists; Female; Germany; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physicians; Pilot Projects; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Young Adult | 2015 |
Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration.
Topics: Administration, Cutaneous; Adult; Area Under Curve; Asian People; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Male; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; White People; Young Adult | 2016 |
Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy korean volunteers.
Topics: Adult; Asian People; Dopamine Agonists; Double-Blind Method; Female; Headache; Humans; Male; Middle Aged; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Young Adult | 2015 |
Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Apathy; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2015 |
A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
Topics: Aged; Chronic Pain; Dopamine Agonists; Double-Blind Method; Female; Humans; Internationality; Male; Middle Aged; Pain Measurement; Parkinson Disease; Pilot Projects; Prospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2016 |
Rotigotine's effect on PLM-associated blood pressure elevations in restless legs syndrome: An RCT.
Topics: Adolescent; Adult; Aged; Blood Pressure; Blood Pressure Determination; Dopamine Agonists; Double-Blind Method; Heart Rate; Humans; Least-Squares Analysis; Middle Aged; Nocturnal Myoclonus Syndrome; Photoperiod; Polysomnography; Restless Legs Syndrome; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome; Young Adult | 2016 |
Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Topics: Adult; Aged; China; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2016 |
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Apathy; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2016 |
Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Depression; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome; Vomiting | 2016 |
Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor.
Topics: Accelerometry; Aged; Dopamine Agonists; Female; Humans; Hypokinesia; Male; Middle Aged; Parkinson Disease; Sleep; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Topics: Aged; Antiparkinson Agents; Asian People; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Randomized, double-blind, crossover study of the adhesiveness of two formulations of rotigotine transdermal patch in patients with Parkinson's disease.
Topics: Adhesiveness; Administration, Cutaneous; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2018 |
Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.
Topics: Actigraphy; Aged; Clinical Decision-Making; Dopamine Agonists; Female; Humans; Male; Parkinson Disease; Pilot Projects; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Wearable Electronic Devices | 2019 |
24 other study(ies) available for oxybutynin and thiophenes
| Article | Year |
|---|---|
In brief: transdermal rotigotine (Neupro).
Topics: Antiparkinson Agents; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2012 |
[Local effects of transdermal treatment with rotigotine].
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Drug Evaluation; Drug Therapy, Combination; Equipment Failure; Erythema; Female; Humans; Male; Middle Aged; Pain; Patient Acceptance of Health Care; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2013 |
A case of cluster headache treated with rotigotine: clinical and neurophysiological correlates.
Topics: Adult; Blinking; Cluster Headache; Dopamine Agonists; Habituation, Psychophysiologic; Humans; Male; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2013 |
Transdermal rotigotine in restless legs syndrome: impulse control disorders.
Topics: Administration, Cutaneous; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Restless Legs Syndrome; Risk Assessment; Risk Factors; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2014 |
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Parkinson Disease; Polysomnography; Severity of Illness Index; Sleep; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2015 |
Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
Topics: Adult; Aged; Dopamine Agonists; Female; Humans; Male; Middle Aged; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Area Under Curve; Biotransformation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Dopamine Agonists; Drug Interactions; Genotype; Healthy Volunteers; Humans; Male; Middle Aged; Omeprazole; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Proton Pump Inhibitors; South Africa; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Young Adult | 2014 |
Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.
Topics: Administration, Cutaneous; Aged; Dermatitis, Allergic Contact; Dopamine Agonists; Humans; Parkinson Disease; Patch Tests; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2016 |
Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease.
Topics: Aged; Dopamine Agonists; Female; Hong Kong; Humans; Male; Parkinson Disease; Polysomnography; Prospective Studies; REM Sleep Behavior Disorder; Severity of Illness Index; Sleep, REM; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2016 |
A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
Topics: Administration, Oral; Aged; Benzothiazoles; Dopamine Agonists; Drug Synergism; Female; Humans; Indoles; Male; Pramipexole; Restless Legs Syndrome; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Time Factors; Transdermal Patch | 2016 |
Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report.
Topics: Aged; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
[Efficacy of Topical Agents for Symptomatic Treatment of Rotigotine Patch-Induced Skin Disorders].
Topics: Adult; Aged; Aged, 80 and over; Dopamine Agonists; Female; Humans; Male; Middle Aged; Retrospective Studies; Skin Diseases; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biological Availability; Clinical Trials, Phase I as Topic; Dopamine Agonists; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Models, Biological; Models, Theoretical; Skin Absorption; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Young Adult | 2018 |
An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2018 |
Vascular Parkinsonism sensitive to Rotigotine therapy is found in aged patients: a clinical case description.
Topics: Aged, 80 and over; Cerebral Infarction; Dopamine Agonists; Female; Humans; Magnetic Resonance Imaging; Necrosis; Parkinson Disease, Secondary; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; White Matter | 2018 |
Transdermal rotigotine patch in Parkinson's disease with a history of intestinal operation.
Topics: Adult; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Intestine, Small; Malabsorption Syndromes; Male; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2018 |
Long-term treatment with rotigotine in drug-naïve PSP patients.
Topics: Aged; Dopamine Agonists; Female; Humans; Male; Middle Aged; Supranuclear Palsy, Progressive; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2019 |
The combination of levomepromazine (methotrimeprazine) and rotigotine enables the safe and effective management of refractory nausea and vomiting in a patient with idiopathic Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Antipsychotic Agents; Dopamine Agonists; Female; Humans; Methotrimeprazine; Nausea; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome; Vomiting | 2019 |
Contact leukoderma induced by rotigotine transdermal patch (Neupro®).
Topics: Dopamine Agonists; Female; Humans; Hypopigmentation; Middle Aged; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2019 |
Safety and efficacy of Rotigotine in hospedalized patients with Vascular Parkinsonism aged 75 and older: effects on movement, praxis capacities, time-space orientation, quality of life and adherence to medical therapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Brain Ischemia; Cognition; Dopamine Agonists; Female; Geriatric Assessment; Hospitalization; Humans; Inpatients; Male; Movement; Parkinson Disease, Secondary; Patient Safety; Prospective Studies; Quality of Life; Risk Assessment; Sampling Studies; Severity of Illness Index; Stroke; Tetrahydronaphthalenes; Thiophenes; Time Perception; Transdermal Patch; Treatment Outcome | 2019 |
Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2019 |
Investigation on the effect of deep eutectic formation on drug-polymer miscibility and skin permeability of rotigotine drug-in-adhesive patch.
Topics: Adhesives; Administration, Cutaneous; Animals; Chemistry, Pharmaceutical; Crystallization; Drug Liberation; Male; Permeability; Polymers; Rabbits; Rats; Rats, Wistar; Skin; Skin Absorption; Spectroscopy, Fourier Transform Infrared; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2020 |
Idiopathic Parkinson's Disease at the End of Life: A Retrospective Evaluation of Symptom Prevalence, Pharmacological Symptom Management and Transdermal Rotigotine Dosing.
Topics: Administration, Cutaneous; Death; Dopamine Agonists; Humans; Parkinson Disease; Prevalence; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2021 |
Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Quality of Life; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2022 |